PALLAS: PALbociclib CoLlaborative Adjuvant Study

Recruiting

18 years - 99 years

All

Phase 3

24 participants needed

1 Location

Brief description of study

The purpose of this study is to compare any good and bad effects of using 2 years of the investigational drug Palbociclib in combination with standard anti-hormone therapy to using standard anti-hormone therapy alone and to evaluate the likelihood that invasive breast cancer returns.

Detailed description of study

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Breast cancer, breast, hormone
Age: 18 years - 99 years
Gender: All

Updated on 04 Aug 2024. Study ID: 825836

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Brief description of study

Detailed description of study

Eligibility of study

Find a site

Interested in the study